Stefani Spranger

Stefani Spranger

Howard S. and Linda B. Stern Career Development Assistant Professor

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.





Paul Thompson



Assistant Phone


  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.


  • Forbeck Fellow, 2015

Recent Publications

  1. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Bedognetti, D, Ceccarelli, M, Galluzzi, L, Lu, R, Palucka, K, Samayoa, J, Spranger, S, Warren, S, Wong, KK, Ziv, E et al.. 2019. J Immunother Cancer 7, 131.
    doi: 10.1186/s40425-019-0602-4PMID:31113486
  2. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Luke, JJ, Bao, R, Sweis, RF, Spranger, S, Gajewski, TF. 2019. Clin. Cancer Res. 25, 3074-3083.
    doi: 10.1158/1078-0432.CCR-18-1942PMID:30635339
  3. WNT Signaling in Cancer Immunosurveillance. Galluzzi, L, Spranger, S, Fuchs, E, López-Soto, A. 2019. Trends Cell Biol. 29, 44-65.
    doi: 10.1016/j.tcb.2018.08.005PMID:30220580
  4. A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion. Horton, B, Spranger, S. 2018. Immunity 49, 11-13.
    doi: 10.1016/j.immuni.2018.07.001PMID:30021140
  5. A team effort: natural killer cells on the first leg of the tumor immunity relay race. Fessenden, TB, Duong, E, Spranger, S. 2018. J Immunother Cancer 6, 67.
    doi: 10.1186/s40425-018-0380-4PMID:29986768
  6. Impact of oncogenic pathways on evasion of antitumour immune responses. Spranger, S, Gajewski, TF. 2018. Nat. Rev. Cancer 18, 139-147.
    doi: 10.1038/nrc.2017.117PMID:29326431
  7. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Gajewski, TF, Corrales, L, Williams, J, Horton, B, Sivan, A, Spranger, S. 2017. Adv. Exp. Med. Biol. 1036, 19-31.
    doi: 10.1007/978-3-319-67577-0_2PMID:29275462
  8. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Horton, BL, Williams, JB, Cabanov, A, Spranger, S, Gajewski, TF. 2018. Cancer Immunol Res 6, 14-24.
    doi: 10.1158/2326-6066.CIR-17-0249PMID:29097422
  9. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Spranger, S, Dai, D, Horton, B, Gajewski, TF. 2017. Cancer Cell 31, 711-723.e4.
    doi: 10.1016/j.ccell.2017.04.003PMID:28486109
  10. Innate immune signaling and regulation in cancer immunotherapy. Corrales, L, Matson, V, Flood, B, Spranger, S, Gajewski, TF. 2017. Cell Res. 27, 96-108.
    doi: 10.1038/cr.2016.149PMID:27981969
More Publications


Photo credit: Kelsey Montgomery